Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase
Rhea-AI Summary
Inspira Technologies (Nasdaq: IINN) has terminated its February 17, 2026 sales agreement with A.G.P./Alliance Global Partners and its December 12, 2025 Standby Equity Purchase Agreement with YA II PN, Ltd.
The company delivered formal written notices and stated there are no outstanding obligations or further advances under either agreement, citing a disciplined capital structure as it prepares for its next strategic phase.
Positive
- Termination confirms no outstanding obligations under either facility
- Signals focus on a disciplined capital structure
- Moves company into a defined next strategic phase
Negative
- Eliminates near-term access to ATM sales facility
- Removes standby equity purchase backstop
Key Figures
Market Reality Check
Peers on Argus
IINN was up 1.02% pre-news while peers showed mixed moves; scanner names like COCH were up 7.33% and NSYS down 4.05%, suggesting stock-specific rather than sector-wide drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Full-year results | Neutral | -23.1% | Reported 2025 financials, purchase orders, and a registered direct offering. |
| Feb 25 | Nasdaq deficiency notice | Negative | -0.1% | Notified of non-compliance with Nasdaq market value of publicly held shares. |
| Feb 18 | U.S. deployment | Positive | -2.5% | ART100 deployed at a top New York academic medical center for evaluation. |
| Feb 17 | Conference marketing | Positive | +0.8% | Planned ART100 showcase at AmSECT 2026 via U.S. distributor Glo-Med. |
| Feb 12 | Bid price notice | Negative | -0.0% | Nasdaq notice for failing to meet the $1.00 minimum bid price requirement. |
Recent positive commercial and technical updates often saw muted or negative price reactions, while regulatory deficiency notices had only slight share price impact.
This announcement fits into a period where Inspira balanced commercialization progress with financing and listing challenges. On Mar 26, 2026, full-year 2025 results highlighted initial ART100 revenue, sizable purchase orders, and a $4.75M registered direct offering. February brought Nasdaq notices on market value and minimum bid price, alongside expanding ART100 deployment and U.S. marketing at AmSECT 2026. Today’s termination of the ATM and SEPA facilities follows those financing steps and recent capital markets activity.
Regulatory & Risk Context
Inspira has an active Form F-3/A shelf filed on 2025-11-25, allowing offerings of up to $75,000,000 in ordinary shares, warrants and units. The shelf has been used at least once via a 424B5 offering on 2025-12-15. Today’s termination of the ATM and SEPA facilities removes those specific equity lines but does not affect the broader shelf capacity as described.
Market Pulse Summary
This announcement ends both the ATM sales agreement and the Standby Equity Purchase Agreement, signaling a shift in how Inspira approaches equity financing. It follows a period of capital raises, Nasdaq listing deficiency notices, and growing ART100 commercialization efforts. Investors may monitor whether future funding relies on the existing $75,000,000 F-3 shelf, as well as execution on purchase orders and commercial deployments, to evaluate how the next strategic phase supports balance sheet strength.
Key Terms
standby equity purchase agreement financial
AI-generated analysis. Not financial advice.
RA'ANANA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the termination of its sales agreement with A.G.P./Alliance Global Partners, dated February 17, 2026, and its Standby Equity Purchase Agreement with YA II PN, Ltd, dated December 12, 2025.
The Company has delivered formal written notices to terminate these financing facilities, with no outstanding obligations or further advances to be made under either agreement by either of the parties to the respective agreements.
The decision reflects the Company’s commitment to maintaining a disciplined capital structure, as it prepares for its next strategic phase.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses its expectations regarding its strategic direction and upcoming initiatives, its intention to maintain a disciplined capital structure, preparation for its next strategic phase, and the timing and content of any future updates regarding its strategic plans. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
Investor Relations Contact
Arx Investor Relations
North American Equities Desk
inspira@arxhq.com
FAQ
What did Inspira Technologies (IINN) announce on March 31, 2026 about its financing facilities?
How does the termination of the ATM and SEPA affect Inspira Technologies' (IINN) obligations?
Why did Inspira Technologies (IINN) end the A.G.P. sales agreement and YA II SEPA?
What immediate financing options did Inspira Technologies (IINN) remove by terminating these agreements?
Where can investors find more information about Inspira Technologies (IINN) termination notices dated March 31, 2026?
